Apimeds Pharmaceuticals US, Inc. (APUS)
$3.87-$0.08 (-2.03%) Today
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
No Form 4 activity for APUS in the last 90 days.
12 Form 4 filings on record, the earliest from Oct 15, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Carol A. O'Donnell - Director | Grant or award | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Jakap Koo - Director | Grant or award | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Hankil Yoon - Director | Grant or award | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Bennett Weintraub - Director | Grant or award | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Elona Kogan - Director | Grant or award | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Elona Kogan - Director | Grant or award | Stock Option (right to buy) | 3,000 | $0.00 | - | |
| Carol A. O'Donnell - Director | Grant or award | Stock Option (right to buy) | 3,000 | $0.00 | - | |
| Erik C. Emerson - Officer | Grant or award | Stock Option (right to buy) | 215,000 | $0.00 | - | |
| Jakap Koo - Director | Grant or award | Stock Option (right to buy) | 3,000 | $0.00 | - | |
| Hankil Yoon - Director | Grant or award | Stock Option (right to buy) | 3,000 | $0.00 | - | |
| Bennett Weintraub - Director | Grant or award | Stock Option (right to buy) | 3,000 | $0.00 | - | |
| Christopher Kim - Officer | Grant or award | Stock Option (right to buy) | 3,000 | $0.00 | - |
Apimeds Pharmaceuticals US, Inc. (APUS) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-11-13. The full record for APUS runs to 12 Form 4 filings, the earliest from 2025-10-15. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of APUS were filed in the last 90 days.
No insider sales of APUS were filed in the last 90 days.
This page tracks APUS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add APUS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
